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Background: Chronic pulmonary obstructive disease (COPD) has become the fourth leading cause of death
worldwide. Cigarette smoking induces neutrophil elastase (NE) and contributes to COPD, but the detailed
mechanisms involved are not fully established. In an animal model of pulmonary emphysema, there are increased
expressions of placenta growth factor (PlGF) and lung epithelial (LE) cell apoptosis. This study hypothesized that
excessive NE may up-regulate PlGF and that PlGF-induced LE apoptosis mediates the pathogenesis of pulmonary
emphysema.
Methods: Human bronchial epithelial cells, BEAS-2B, and primary mouse type II alveolar epithelial cells were treated
with NE. The PlGF promoter activity was examined by luciferase activity assay, while PlGF expression and secretion
were evaluated by RT-PCR, Western blotting, and ELISA. Both cell lines were treated with PlGF to evaluate its effects
and the downstream signaling pathways leading to LE cell apoptosis. PlGF knockout and wild-type mice were
instilled with NE to determine the roles of PlGF and its downstream molecules in NE-promoted mice pulmonary
apoptosis and emphysema phenotype.
Results: The transcriptional factor, early growth response gene-1, was involved in the NE-promoted PlGF promoter
activity, and the expression and secretion of PlGF mRNA and protein in LE cells. PlGF-induced LE cell apoptosis and
NE-induced mice pulmonary apoptosis and emphysema were mediated by the downstream c-Jun N-terminal kinase
(JNK) and protein kinase C (PKC)δ signaling pathways.
Conclusion: The NE-PlGF-JNK/PKCδ pathway contributes to the pathogenesis of LE cell apoptosis and emphysema.
PlGF and its downstream signaling molecules may be potential therapeutic targets for COPD.
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EmphysemaBackground
Chronic pulmonary obstructive disease (COPD) is predicted
to become the fourth leading cause of death worldwide by
2030 [1,2]. Due to the aging population and increasing num-
ber of smokers, the burden of medical and social resources for
COPD is estimated to be US$47 trillion by 2030 [3]. Although
there are many mediators (i.e., inflammatory cells, lipids,
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unless otherwise stated.mokines, cytokines, growth factors, and proteases) and
cellular pathways (e.g., inflammation, apoptosis, senes-
cence and repair) involved in the pathogenesis of COPD,
increasing evidence indicates that proteases provide vital
contributions to all mediators and cellular pathways [4,5].
However, to date, the detailed pathogenic mechanisms of
protease-mediated COPD are not fully understood [3,6].
In developed countries, the major factor for the patho-
genesis and progression of COPD is cigarette smoke (CS).
Exposure to CS results in chronic inflammation, elevated oxi-
dative stress, and protease-anti-protease imbalance within the
respiratory system [7]. The protease-anti-protease im-
balance is triggered by the infiltration of inflammatory cells
like neutrophils, macrophages, and CD8+ T lymphocytes. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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phages, neutrophil elastase (NE), and matrix metallopro-
teinase (MMP)-12, degrade their respective inhibitors.
Thus, the interaction promotes protease-anti-protease
imbalance and destroys the pulmonary parenchyma with
alveolar space dilatation, i.e. emphysema, which is a major
component of COPD [12].
Neutrophil elastase is a secreted serine protease that
degrades extracellular matrix like elastin, which contributes
to the recoil capacity of alveoli [13]. Other than proteolytic
activity, NE up-regulates elafin, interleukin-8, MUC4, and
MUC5AC, and promotes the secretion of mucin in LE cells
[14-18]. Excessive NE also results in LE cell apoptosis
through protease-activated receptor (PAR)-1, which is
abrogated by treatment with retinoic acid [19,20].
Apoptosis of LE cells results in the loss of lung paren-
chyma and is a potential pathogenic mechanism for em-
physema and COPD [21]. Placenta growth factor (PlGF)
induces apoptosis of type II alveolar epithelial cells (AEC
II) such that PlGF transgenic mice develop a phenotype of
pulmonary emphysema [22]. PlGF is a member of the vas-
cular endothelial growth factor family that promotes
angiogenesis [23,24]. PlGF expression is abundant in the
placenta, heart, lungs, thyroid, brain, and skeleton muscle
during fetal development, but declines in adulthood [25].
Higher levels of PlGF have been shown in serum and
broncho-alveolar lavage (BAL) fluid of COPD patients and
the PlGF levels is inversely proportional to lung function
deterioration [26]. Porcine pancreatic elastase (PPE), a
recombinant porcine elastase for the animal model of
emphysema, has also been shown to increase PlGF ex-
pression in LE cells and promote LE cells apoptosis [27].
However, the role of NE in human COPD has not been
established.
Under the hypothesis that NE, like PPE, up-regulates
PlGF expression and leads to LE cell apoptosis and pul-
monary emphysema. This study demonstrates that the
NE-promoted PlGF expression and secretion in LE cells
and lungs. Early growth response gene (Egr)-1 is a tran-
scriptional factor responsible for the up-regulation of
PlGF by NE in LE cells. PlGF induces apoptosis through
the c-Jun N-terminal kinase (JNK) and protein kinase C
(PKC)δ signaling pathways. Ablation of PlGF protects
mice from NE-induced pulmonary apoptosis and em-
physema. Thus, NE-induced PlGF and the downstream
JNK/PKCδ signaling pathways contribute to the patho-
genesis of pulmonary emphysema and COPD. Both
PlGF and its downstream signaling pathways may be
potential therapeutic targets for COPD.
Materials and methods
Reagents
Rabbit antibodies for phosphor-P38 MAPK (p-P38 MAPK),
P38 MAPK, MTF-1, p-JNK and p-PKCδ were obtainedfrom Cell Signaling Technology (Beverly, MA, USA).
Antibodies for PlGF, JNK, PKC, and Egr-1, mouse and
human PlGF siRNA, mouse and human PKCδ siRNA, and
the corresponding scramble siRNA were purchased from
Santa Cruz (Santa Cruz, CA, USA), while NE was
purchased from Abcam (Cambridge, MA, USA). Trizol
reagent, SuperScript III Reverse Transcriptase and Lipo-
fectamine 2000 were obtained from Invitrogen (Carlsbad,
CA, USA). Mouse antibody for beta-actin and rabbit
antibody for HIF-1alpha were purchased from Genetex
(Irvine, CA, USA). Human and mouse recombinant
PlGF protein and an enzyme-linked immuno-sorbent
assay (ELISA) kit were obtained from R and D Systems
(Minneapolis, MN, USA).
A dual-luciferase reporter assay system was obtained
from Promega (Madison, WI, USA). Hematoxylin and
Eosin, Chromatin immuno-precipitation (ChIP) Assay Kit,
and EZ-Zyme Chromatin Prep Kit were purchased from
Merck-Millipore (Boston, MA, USA). An in situ cell Death
Detection Kit and X-tremeGENE HP DNA Transfection
Reagent were purchased from Roche (Mannheim,
Germany). The FITC Annexin V apoptosis detection
Kit I was obtained from BD Biosciences (San Jose, CA,
USA). The JNK inhibitor, SP600125, was obtained from
Enzo Life Science (Plymouth Meeting, PA, USA). A
SuperSensitive Polymer-HRP IHC Detection System was
purchased from Biogenex (Fremont, CA, USA).
Animals
This study conformed to the Guidelines for the Care
and Use of Laboratory Animals published by the
United States National Institutes of Health (NIH Publi-
cation No. 85–23, revised 1996). All of the animal
experiments were approved by the Institutional Animal
Care and Use Committee (IACUC) of the Laboratory
Animal Center, College of Medicine and Public Health
of National Taiwan University. Eight-week-old male
C57BL/6 wild type (WT) mice were purchased from
the Laboratory Animal Center, College of Medicine
and College of Public Health, National Taiwan Univer-
sity. The PlGF knockout (KO) mice in B6 background
were provided by Dr. Po-Nien Tsao (National Taiwan
University, Taiwan).
Cell culture
Human bronchial epithelial cells, BEAS-2B (ATCC num-
ber CRL-9609), were cultured in F12 nutrient mixture
(Carlsbad, CA, USA) with 0.5 ng/ml recombinant epider-
mal growth factor, 500 ng/ml hydrocortisone, 0.005 mg/ml
insulin, 0.035 mg/ml bovine pituitary extract, 500 nM
ethanolamine, 500 nM phosphoethanolamine, 0.01 mg/ml
transferrin, 6.5 ng/ml 3, 3′, 5-triiodothyronine, 500 ng/ml
epinephrine, 0.1 ng/ml retinoic acid, 10% FCS 100 unit/ml
penicillin, and 100 μg/ml streptomycin in a humidified 95%
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alveolar epithelial cells (AEC II) and culture medium were
purchased from chi scientific (Maynard, MA, USA). Pri-
mary normal human bronchial epithelial (NHBE) cells
were kindly provided by Dr. Reen Wu at University of
California, Davis.
Plasmids
Human genomic DNA was extracted from BEAS-2B by
a Quick-gDNA MiniPrep kit (Zymo Research, CA,
USA). The 2.0 kb human PlGF promoter region was
amplified from human genomic DNA using polymerase
chain reaction (PCR) performed with Hi Fi Taq DNA
polymerase (Geneaid, Taipei, Taiwan) as follows: 2 mi-
nutes at 94°C, then 15 sec at 94°C, 30 sec at 59°C, and
2 min and 30 sec at 72°C for 35 cycles. The primers for
2.0 kb human PlGF promoter region were 5′-GCG
GTAC CCA AAC TCA TAC ACA ATA GAC-3′ (for-
ward primer; italic, KpnI site) and 5′-TTA AGCT TCC
GTA GGT AAG GCT GTG GCT-3′ (reverse primer;
italic, HindIII site). The amplified DNA fragments were
cloned into pGL3 vector (Promega, WI, USA) and the
sequences were confirmed by DNA sequence analysis.
The pGL3 with mouse PlGF promoter was as previously
described [27].
Enzyme-linked immuno-sorbent assay (ELISA)
Cellular medium from BEAS-2B and AEC II, and BAL fluid
from mice were analyzed by a PlGF ELISA kit (R & D, MN,
USA) according to the manufacturer’s instructions.
Luciferase reporter assay
The BEAS-2B and AEC II were co-transfected with the
pGL3-PlGF promoter and pRenilla for 24 h via Lipofec-
tamine 2000 and X-tremeGENE HP DNA Transfection
Reagent, and then collected and analyzed on a dual-
luciferase reporter assay system (Promega, WI, USA) using
a lumicounter Packard BL10000 according to the manufac-
turer’s instructions.
Protein extraction and immuno-blot analysis
The BEAS-2B and AEC II were lysed using RIPA lysis
buffer (Genestar, Taipei, Taiwan), containing 1% NP-40,
0.1% SDS, 150 mM sodium chloride, 0.5% sodium deox-
ycholate, and 50 mM Tris with a protease inhibitor
cocktail (Bionovas, Toronto, Canada) and PhosSTOP
(Roche, Basilea, Switzerland). The cell lysates were centri-
fuged at 12,000 rpm for 5 min and the resulting super-
natant was collected.
The extracted protein was quantified by protein assay.
Equal amounts of protein were separated using 10%
SDS-polyacrylamide gel electrophoresis and transferred
to Immobilon-P membranes (Millipore, MA, USA). After
blocking with 5% skimmed milk, the membranes wereincubated with various primary antibodies and then incu-
bated with the corresponding secondary antibodies. The
protein bands were detected using an Immobilon Western
Chemi-luminescent HRP Substrate (Millipore, MA, USA)
and quantified by the ImageQuant 5.2 software (Healthcare
Bio-Sciences, PA, USA).
Terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) assay
The BEAS-2B and AEC II, and OCT-embedded lung tis-
sue from the mice were analyzed for the apoptosis level
using an in situ cell Death Detection Kit (Roche, Basilea,
Switzerland) according to the manufacturer’s instruc-
tions. Fluorescence-positive cells were photographed by
a Leica DM 4000B microscope (Leica, Solms, Germany).
Flow cytometry analysis
The BEAS-2B and AEC II were analyzed on a FITC
Annexin V apoptosis detection Kit I (Franklin Lakes, NJ,
USA) according to the manufacturer’s instructions. The
FITC-positive cells were analyzed using a FACS Calibur
flow cytometer (Becton Drive, NJ, USA).
Immuno-histochemistry (IHC) assay
Paraffin was removed from paraffin-embedded tissue sec-
tions by xylene, dehydrated by ethanol, and re-hydrated by
PBS. After treatment with 3% H2O2, the sections were
applied to a SuperSensitive Polymer-HRP IHC Detection
System (Biogenex, CA, USA) and incubated with PlGF,
p-JNK, and p-PKCδ antibodies as primary antibodies. The
stained-sections were photographed using a Leica DM
4000B microscope (Leica, Solms, Germany).
Hematoxylin and eosin (H and E) staining
Paraffin was removed from paraffin-embedded tissue sec-
tions by xylene, dehydrated by ethanol, and re-hydrated by
PBS. Sections stained with H and E were photographed by
a Leica DM 4,000 B microscope (Leica, Solms, German).
NE-induced emphysema
The dose of NE was four-fold higher than that of porcine
pancreatic elastase according to previous report [28] and
the methodology of intra-tracheal instilling NE was per-
formed as previously described [29]. Briefly, eight-week-old
mice were intra-tracheally given saline (CON), 400 mU/ml
NE (NE), 400 mU/ml NE with 50 mg/kg JNK inhibitor
SP600125 (NE SP), 3 mg/kg scramble siRNA (NE Si-Sc),
3 mg/kg mouse PKCδ siRNA (NE Si-PK) and 3 mg/kg
PlGF siRNA (NE Si-Pl) weekly for one month. The dose of
siRNA instillation was according to a previous study
[27,30]. Each experimental group had five mice and the
processing of lung tissues and BAL fluid were performed as
previously described [27,29].
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Total RNA of BEAS-2B and AEC II were extracted by
Trizol Reagent (Invitrogen, CA, USA) according to the
manufacturer’s instructions. Total RNA (5 μg) was used
in the RT reactions using a SuperScript III Reverse
Transcriptase kit (Invitrogen, CA, USA) according to
the manufacturer’s instructions to synthesize the cDNA.
The human PlGF and glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH) cDNA fragments were amplified
from the cDNA by PCR, performed with Dream Taq
DNA polymerase (Fermentas, MA, USA) as follows:
5 min at 95°C, then 30 sec at 98°C, 30 sec at 59°C, and
1 min at 72°C for 35 cycles. The primers for 164 bp hu-
man PlGF cDNA fragment were 5′-GGC GAT GAG*
*
























   






















   
   









   





































   


























   
   













Figure 1 NE-induced PlGF promoter activity is mediated by Egr-1. (A,
evaluated by luciferase activity. (B) Hypoxia inducible factor (HIF)-1alpha an
were analyzed by Western blot analysis. (D) The association of Egr-1 and PlGF p
Data are presented as mean ± SEM. *p< 0.05 vs. vehicle-treated group.AAT CTG CAC TGT-3′ and 5′-GAA GAT GAA GCC
GGA AAG GTG-3′. The primers for 530 bp human
GAPDH cDNA fragment were 5′-GGG CGC CTG GTC
ACC AGG GCT G-3′ and 5′-GGG GCC ATC CAC
AGT CTT CTG-3′. The primer sets for mouse PlGF
and GAPDH was as previously described [27].
Chromatin immuno-precipitation (ChIP)
Genomic DNA fragment from BEAS-2B were prepared
by the EZ-Zyme Chromatin Prep Kit (Millipore, MA,
USA) and analyzed using the Chromatin immuno-
precipitation (ChIP) Assay Kit (Millipore, MA, USA) to
evaluate the associated levels of Egr-1 and PlGF pro-
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E, and F) The placenta growth factor (PlGF) promoter activity was
d metal-regulatory transcription factor (MTF)-1, (C) Egr-1, and β-actin





   
   









   





















   
   








   

























   









































   
   









   


























   
   








   
























   
























   
   









   





















   
   








   

























   





































Scramble siRNA Egr-1 siRNA
Scramble siRNA Egr-1 siRNA
Scramble siRNA Egr-1 siRNA
* *
Figure 2 NE-induced PlGF expression and secretion are mediated by Egr-1. (A-C) The mRNA level of PlGF was determined by reverse-transcriptional
polymerase chain reaction (RT-PCR) with primer sets for PlGF and GAPDH cDNA. (D-F) Cellular lysates were also subjected to Western blot analysis with
antibodies for PlGF and β-actin. (G-I) The PlGF in the culture medium was detected by enzyme-linked immuno-sorbent assay (ELISA). Data are presented
as mean ± SEM. *p< 0.05 vs. vehicle-treated group.

























   
















































   










































   









































   





















Figure 3 PlGF activates JNK and PKCδ signaling pathways in LE cells. (A-C) AEC II and (D) BEAS-2B were treated with 100 ng/ml recombinant
human mouse PlGF respectively for 0–24 h. Cellular lysates were subjected to Western blot analysis with antibodies for phosphorylated p38 MAPK
(p-p38 MAPK) and p38 MAPK (A), phosphorylated JNK (p-JNK) and JNK (B), phosphorylated PKCδ (p-PKCδ) and PKCδ (C and D). Data are presented as
mean ± SEM. *p< 0.05 vs. vehicle-treated group.
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CCA AGA ATG CCT ATG TCC ATT C-3′ and 5′-TTA
AGC TTC CGT AGG TAA GGC TGT GGC T-3′) were
used to amplify the human PlGF promoter fragment ac-
cording to the manufacturer’s instructions.
Statistical analysis
The results were presented as mean ± SEM from five in-
dependent experiments and animals. The Mann–Whitney
test was used to compare two independent groups.
Kruskal-Wallis with Bonferroni post hoc analysis was used
for multiple testing. Statistical analyses were performed
using the SPSS version 8.0 (SPSS Inc., IL, USA). Statistical
significance was set at p < 0.05.
Results
NE increased PlGF promoter activity by Egr-1 in LE Cells
The results revealed that treatment with 100–300 mU/ml
NE for 24 h significantly increased PlGF promoter activitydose-dependently in human bronchial epithelial cells,
BEAS-2B, and primary mouse type II alveolar epithelial
cell (AEC II) (Figure 1A). Previous studies indicated
that several conserved metal response elements (MRE)
and hypoxia response elements (HRE) reside in mouse
or human PlGF promoter regions [31,32]. However,
treatment with 300 mU/ml NE did not alter the
expression of mental-regulatory transcription factor
(MTF)-1 and hypoxia inducible factor (HIF)-1α
(Figure 1B).
There was a conserved Egr-1 response element in the
human and mouse PlGF promoter regions near the
transcriptional start site [32,33]. Western blotting
revealed that 300 mU/ml NE challenge transiently in-
creased Egr-1 expression in BEAS-2B (Figure 1C). By
ChIP, treatment of 300 mU/ml NE for 1 h triggered
the binding of Egr-1 and PlGF promoter fragments in
BEAS-2B (Figure 1D) and pre-treatment with Egr-1







PlGF 50 ng/ml PlGF 100 ng/ml











PlGF 100 ng/ml PlGF 100 ng/ml PlGF 100 ng/ml
SP Si-PK
PlGF 0 ng/ml PlGF 25 ng/ml PlGF 50 ng/ml PlGF 100 ng/ml
Si-Sc
PlGF 100 ng/ml PlGF 100 ng/ml PlGF 100 ng/ml
SP Si-PK
Figure 4 PlGF triggers LE cell apoptosis via JNK and PKCδ signaling pathways. The PlGF-induced apoptosis was evaluated by (A) annexin
V-FITC stained cells in flow cytometry assay and (B) fluorescent cells in terminal deoxynucleotidyl transferase dUTP nick end label (TUNEL) assay.
Scale bar = 100 μm.
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Thus, NE increased PlGF promoter activity through
the association of Egr-1 and the PlGF promoter
fragment.
NE increased PlGF expression in LE Cells
NE (100 mU/ml) had been reported to up-regulate ela-
fin expression in A549 cells [14] and PlGF was majorly
secreted by AEC II [22,34]. To test whether NE could
induce PlGF expression, BEAS-2B and AECII were
treated with of 0–300 mU/ml NE for 24 h. PlGF mRNA
and protein level were increased after NE challenge
in a dose-dependent manner and Egr-1 siRNA pre-
treatment abrogated the NE-induced PlGF mRNA
(Figure 2A-C) and protein (Figure 2D-F) expressions
in BEAS-2B and AEC II. Moreover, Egr-1 siRNA also
blocked the NE-induced PlGF secretion in medium of
BEAS-2B and AEC II (Figure 2G-I).
Moreover, NE increased the PlGF expression in
endothelial cell but not in fibroblast cell (Additional
file 1 and Additional file 2: Figures S1A and S1B).
Taken together, other than natural activity of proteoly-
sis, NE increased the PlGF expressions and promoted
PlGF secretion.PlGF induced apoptosis in LE Cells via JNK and PKCδ
signaling pathways
A previous study indicated that 100 ng/ml PlGF in-
duced MLE-15 cell apoptosis with an unknown mech-
anism [22]. It has been previously demonstrated that
PlGF increased apoptosis in MLE-15 cells and BEAS-
2B via JNK and p38 mitogen-activated protein kinase
(MAPK) signaling pathways [27,35]. In order to con-
firm and explore the mechanisms underlying PlGF-
induced LE cells apoptosis, BEAS-2B and AEC II were
treated with 100 ng/ml recombinant PlGF for 24 h.
Although the results of Western blot analysis revealed
that PlGF didn’t activate p38 MAPK significantly, PlGF
induced a prolonged and enhanced phosphorylation of
JNK and PKCδ in AEC II (Figure 3A-C). PlGF also
activated PKCδ pathways in BEAS-2B (Figure 3D).
Blockade of JNK or PKCδ signaling by JNK inhibitor,
SP600125, or transfection with PKCδ siRNA had no
effect on PlGF-activated PKCδ or JNK (Additional file 3:
Figure S2), suggesting no crosstalk between PlGF-activated
JNK and PKCδ signaling pathways.
Further evaluating the roles of JNK and PKCδ in
PlGF-induced apoptosis, BEAS-2B and AEC II were pre-
treated with JNK inhibitor or transfected with PKCδ
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ways, then treated with 0–100 ng/ml PlGF for 24 h. Re-
sults of flow cytometry assay (Figure 4A) and TUNEL
assay (Figure 4B) indicated that first, exogenous PlGF
dose-dependently increased BEAS-2B and AEC II apop-
totic levels and second, the JNK and PKCδ signaling
pathways played crucial roles in PlGF-stimulated LE cell
apoptosis.
The impact of NE-induced endogenous PlGF on NE-
induced LE cell apoptosis was further evaluated in
normal human bronchial epithelial cells (NHBE) with
serum-free medium, which was the applicable condi-
tion for NE-digestion. This study also further proved
that NE caused NHBE apoptosis and blocked endogenous
PlGF signaling by VEGFR1 neutralized antibody, which
attenuated the NE-induced NHBE apoptosis and NE-
activated JNK and PKCδ signaling pathways (Additional file












Figure 5 NE increases expression of PlGF and activation of JNK and P
used for immuno-histochemistry (IHC) analysis and incubated with antibod
PlGF, p-JNK and p-PKCδ in LE cells. (C) Mice broncho-alveolar lavage fluid w
presented as mean ± SEM. *p < 0.05 vs. vehicle-treated group; #p < 0.05 vs.Intra-tracheal instillation of NE increased PlGF expression
and secretion and activated downstream JNK and PKCδ
signaling pathways
The role of PlGF in NE-induced LE cells apoptosis and
emphysema was further confirmed in an animal model.
Wild-type (C57BL/6) and PlGF KO mice were intra-
tracheally treated with saline (CON) or 400 mU/ml NE
(NE) weekly for one month. The pathology of the NE-
treated mice showed elevated PlGF expression in alveo-
lar epithelial cell (Figure 5A) and adjacent endothelial
cells than controls (Additional file 2: Figure S1C). More-
over, NE-treated mice displayed more phosphorylated
JNK and PKCδ levels than the control mice (Figure 5A).
In contrast, ablation of PlGF limited the expression of
PlGF and blocked the NE instillation-induced activation
of JNK and PKCδ (Figure 5B). The BAL fluid from NE-
treated mice also had higher PlGF levels compared to






   















KCδ signaling. (A and B) Paraffin-embedded lung tissue sections were
ies of PlGF, p-JNK and p-PKCδ. Arrow heads indicated positive stain of
as analyzed for the PlGF level by ELISA. Scale bar = 200 μm. Data are
corresponding WT group.
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NE instillation increased the expression and secretion of
PlGF, as well as the activation of JNK and PKCδ in
pulmonary cells.PlGF and PlGF-activated JNK and PKCδ pathways were
involved in NE-induced apoptosis and emphysema in mice
To evaluate the roles of PlGF and JNK/PKCδ signaling in
NE-induced apoptosis and emphysema in an animal model,
50 mg/kg of SP600125, 3 mg/kg scramble siRNA, 3 mg/kg
PKCδ siRNA, or 3 mg/kg PlGF siRNA were co-treated with
NE installation (NE SP, NE Si-Sc, NE Si-PK, or NE Si-Pl)
on WT and PlGF KO mice weekly for one month. TUNEL
assay indicated more abundant apoptotic cells in the
pulmonary tissue of NE-treated mice than control mice
(Figures 6A and E). In contrast, the ablation of PlGF
protected mice from NE-induced pulmonary cell apop-











Figure 6 NE-induced pulmonary apoptosis and emphysema are medi
(A and C) The frozen lung tissue sections were used for TUNEL assay and
E staining. (E) Apoptotic cells in TUNEL assay were quantified and (F) th
evaluated. Scale bar = 200 μm. Data are presented as mean ± SEM. *p < 0.0
vs. corresponding WT group.Moreover, NE-treated mice had the emphysema pheno-
type with enlargement of the alveolar space (Figure 6B), as
evaluated by the mean linear intercept (MLI) (Figure 6F).
On the other hand, ablation of PlGF protected mice from
NE-induced pulmonary destruction (Figure 6D and F). Fur-
thermore, blocking the JNK and PKCδ signaling pathways
(NE SP and NE Si-PK) and silencing of PlGF (NE Si-Pl)
abrogated the levels of NE-induced pulmonary apoptosis
(Figure 6A and E) and attenuated the airspace enlargement
in mice (Figure 6B and F). Thus, the animal model
of elastase-instillation further confirmed that the NE-
increased pulmonary PlGF and the PlGF-activated JNK/
PKCδ signaling pathways were involved in NE-induced
pulmonary apoptosis and emphysema in vivo.
Discussion
There are several conserved trans-elements within the
human and mouse PlGF promoter regions, including

























































ated by PlGF and the downstream JNK/PKCδ signaling pathways.
(B and D) paraffin-embedded lung tissue sections were used for H and
e mean linear intercepts (MLI) from five independent sections were
5 vs. vehicle-treated group; #p < 0.05 vs. NE-treated group; †p < 0.05
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the binding proteins for MRE and HRE. A conserved
Egr-1 response element (CCCCGCCCC) [36] is observed
near the transcriptional start site in both mouse and
human PlGF promoter. Egr-1 is a rapid response transcrip-
tion factor for UV and cigarette smoke stimuli that
up-regulates several genes, including PTEN, microtubule-
associated protein-1 light chain 3, and PAR-1 in LE cells
[36-39]. The Egr-1-upregulated down-stream genes mediate
various cellular functions like cell growth, proliferation,
differentiation, and apoptosis [39]. Egr-1 also has an impact
on the pathogenesis of acute lung injury [40]. A previous
study has demonstrated that NE inhibitors decrease
ventilator-induced Egr-1 expression [41]. In the present
study, NE promotes the transient expression of Egr-1,
which is involved in NE-induced PlGF expression.
The present study demonstrates that NE-induced PlGF
promotes LE cell apoptosis, which corroborate the re-
sults of a previous study [22]. However, unlike previously
established mechanisms of NE-induced LE cell apoptosis
[19,20], this study is the first to show that NE-induces
LE cell apoptosis through PlGF and PlGF-mediated
downstream JNK and PKCδ signaling pathways. The re-
sults of NHBE cells further indicate that NE-promoted
endogenous PlGF contributes to LE cell apoptosis. Fur-
thermore, NE up-regulates PlGF in endothelial cells and
in LE cells. The PlGF-induced LE cell apoptosis may
work through both autocrine and paracrine mechanism.
In addition, it is interesting to know that the up-
regulation of PlGF is identified in an ovalbumin-induced
asthma mice model wherein PlGF promotes neutrophilic
chemotaxis [42]. Therefore, the positive feedback loop
between NE and PlGF in the pathogenesis of COPD
warrants further investigation.
Because of frequently ignored early symptoms and
irreversible pulmonary damage, COPD remains a major
cause of death worldwide [2]. As a chronic disease with
insidious pathogenesis, COPD is difficult to diagnose
early. Useful diagnostic markers will help in the early
diagnosis, early treatment, and reduction of mortality
and morbidity. A previous report indicates that the
NE-digested product, Aα-Val360, may be a marker for
COPD [43]. However, endogenous elastin fragments can
disturb the utility of Aα-Val360 for predicting COPD.
The present study demonstrates that PlGF, which
physiologically appears only in the embryonic stage, may
be a suitable candidate as a diagnostic marker of early
COPD. Based on the IHC results and BAL data in a
previous study [26], COPD patients secrete and express
more PlGF compared to non-COPD controls. Other
than COPD, the up-regulation of PlGF is also associated
with higher risk of several human diseases, including
age-related macular degradation, sickle cell disease, and
most kinds of tumors [24]. As PlGF expression is barelydetectable in healthy adults, further investigation regarding
the association between PlGF and COPD may therefore
support PlGF as a candidate marker for early COPD.
A previous study indicates that mouse PlGF activates p38
MAPK and JNK signaling pathway in mouse alveolar epi-
thelial cells, and that MLE-15 and human PlGF activates
the p38 MAPK and JNK signaling pathway in BEAS-2B. In
the present study, PlGF promotes only JNK and PKCδ in
AEC II cell. The difference in cell systems may explain why
PlGF acts through different down-stream signaling path-
ways. However, the JNK, p38 MAPK, and PKCδ signaling
pathways should all be considered as potential therapeutic
targets aside from PlGF for COPD therapy [44-46].
Conclusions
Using human and mouse LE cells as well as an in vivo
model, this study demonstrates that NE challenge stimu-
lates PlGF expression and secretion, and that PlGF pro-
motes LE cell apoptosis via the JNK and PKCδ signaling
pathways. Thus, PlGF and the downstream JNK/PKCδ
signaling pathways participate in the pathogenesis of
CS-related COPD and should be considered potential
therapeutic targets for COPD therapy.
Additional files
Additional file 1: Supplemental materials and methods.
Additional file 2: Figure S1. Neutrophil elastase (NE) increases placenta
growth factor (PlGF) expression in endothelial cell. BAEC and fibroblast
were treated with neutrophil elastase (NE) (0–300 mU/ml) for 24 h (A and B)
and the cellular lysate were applied for Western blot analysis. (C) Wild type
(WT) mice were intra-tracheally instilled with saline and 400 mU/ml NE weekly
for one month. Paraffin-embedded lung tissue sections were used for
immunohistochemistry (IHC) analysis and incubated with antibodies of
PlGF. The arrow heads in enlarge figures indicated positive stain of PlGF
only showed in endothelial cells of NE group. Data were presented as
mean ± SEM. *p < 0.05 vs. vehicle-treated group.
Additional file 3: Figure S2. PlGF-activated JNK and PKCdelta signaling
pathways have no crosstalk in primary mouse alveolar type II epithelial
cell (AEC II). (A and B) AEC II were transfected with PKCdelta siRNA for
24 h (A) or pretreated with SP600125 for 2 h (B) then treated with PlGF
(100 ng/ml) for 0–24 hr. Cellular lysates were subjected to Western blot
analysis with antibodies for phosphorylated JNK (p-JNK) and JNK (A);
phosphorylated PKCδ (p-PKCδ) and PKCδ (B). Data were presented as
mean ± SEM. *P <0.05 vs. vehicle-treated group.
Additional file 4: Figure S3. NE-upregulated endogenous PlGF
promotes apoptosis and activates JNK and PKCdelta signaling pathways
in primary normal human bronchial epithelial (NHBE). (A and B) NHBE
cells were treated with NE (300 mU/ml) for 0–60 h. Cellular lysates were
subjected to caspase-3 activity (A) and trypanblue inclusion assay (B).
NHBE cells were pretreated with FLT1 neutralizing antibody or IgG for
2 h then treated with NE (300 mU/ml) for 60 h. Cellular lysates were
subjected to Caspase-3 activity (A) and trypanblue inclusion assay (B)
and Western blot analysis with antibodies for phosphorylated JNK
(p-JNK), phosphorylated PKCδ (p-PKCδ), JNK and PKCδ (C). Data were
presented as mean ± SEM. *P <0.05 vs. vehicle-treated group. #P <0.05 vs.
PGF-treated group.
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